Increases in COVID, RSV, and influenza are the result of governments refusal to enact public health measures and address ...

Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Respiratory syncytial virus (RSV) and influenza typically circulate contemporaneously, meaning co-infections are common. Clinical studies of such co-infection have so far yielded conflicting ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

At the peak of the respiratory virus season, there could be between 15 and 25 new weekly hospitalizations for every 100,000 people in the US, according to the analysis. Covid-19 will probably ...

Respiratory syncytial virus (RSV) is a common germ that can settle into your lungs and airways. It's the top cause of upper respiratory infection in babies and toddlers, but anyone can get it.

AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Respiratory syncytial virus (RSV) is a respiratory infection that has similar symptoms as a cold. But it can be serious for expectant parents who are more at risk for complications from the virus.

Discover the latest insights in the "Respiratory Syncytial Virus (RSV) Infections - Global Clinical Trials Review, 2025." This comprehensive report details RSV clinical trial data, including trial ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...